Editorial

Brian I. Carr

Published online: 9 March 2010
© Springer Science+Business Media, LLC 2010

Welcome to The Journal of Gastrointestinal Cancer, 2010. The new year brings in a new editor-in-chief and a vibrant scene in the world of gastrointestinal cancer, with rapid advances in quantitative imaging, novel radiation approaches, new cell cycle and anti-angiogenic agents, predictive proteomic and genomic tumor sample testing and circulating tumor cell assays, and investigation into the role of the new agents in adjuvant and neo-adjuvant therapies.

The journal encourages submissions in all areas of of gastrointestinal cancer, including original articles on clinical and scientific topics relating to disease mechanisms and treatment mechanisms, clinical and experimental tumor biology and therapy, disparities research, psychosocial issues, epidemiology, and cancer genetics. We support meeting summaries, book reviews, and evidence-based hypotheses,

as well as timely reviews on clinical practice and the cancer scene; and we will, from time-to-time, invite debates on currently controversial issues, as well as inviting meeting reports and special commentaries.

We continue to welcome original articles on clinical trials, clinical series, clinical and experimental studies, brief communications, case reports accompanied by literature reviews, and both clinical and research studies on molecular mechanisms of disease and treatments.

The editorial staff encourages your comments and suggestions for both content and for reviewers.

Sincerely, Brian Carr

Editor-in-chief, J. Gastrointestinal Cancer 1/2/2010

B. I. Carr (✉)
Kimmel Cancer Center, Thomas Jefferson University,
Bluemle 519, 233 So 10th St,
Philadelphia, PA 19107, USA
email: brian.carr@kimmelcancercenter.org
email: brian.carr@jefferson.edu